Passive immunization with Pneumovax? 23 and pneumolysin in combination with vancomycin for pneumococcal endophthalmitis
详细信息 查看全文
- 作者：Melissa E Sanders (1)
Sidney Taylor (1)
Nathan Tullos (1)
Erin W Norcross (1)
Quincy C Moore (1)
Hilary Thompson (2)
Lauren B King (1)
Mary E Marquart (1) - 关键词：Streptococcus pneumoniae ; Bacterial endophthalmitis ; Capsule ; Pneumolysin ; Vaccination
- 刊名：BMC Ophthalmology
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：450KB
- 参考文献：1. Ortqvist A, Hedlund J, Kalin M: Streptococcus pneumoniae : epidemiology, risk factors, and clinical features. / Semin Respir Crit Care Med 2005, 26:563-74. CrossRef
2. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, Lefkowitz L, Perkins BA: Bacterial meningitis in the United States in 1995. / New Engl J Med 1997, 337:970-76. CrossRef
3. Overturf GD, American Academy of Pediatrics, Committee on Infectious Diseases: Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. / Pediatrics 2000, 106:367-76. CrossRef
4. Kadioglu A, Andrew P: The innate immune response to pneumococcal lung infection: the untold story. / Trends Immunol 2004, 25:143-49. CrossRef
5. Callegan MC, Booth MC, Jett BD, Gilmore MS: Pathogenesis of gram-positive bacterial endophthalmitis. / Infect Immun 1999, 67:3348-356.
6. Callegan MC, Engelbert M, Parke DW II, Jett BD, Gilmore MS: Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. / Clin Microbiol Rev 2002, 15:111-24. CrossRef
7. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, Kelsey SF: Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. / Am J Ophthalmol 1996, 122:1-7.
8. Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, Ho AC: Changing trends in the microbiologic aspects of postcataract endophthalmitis. / Arch Ophthalmol 2005, 123:341-46. CrossRef
9. Soriano F, Perez-Trallero E, Pallares R, Meseguer MA, Fleites A, Gene A, Gonzalez A, Linares J, Esteban J, Baquero F, Valdes E, Munoz-Almagro C: Streptococcus pneumoniae endophthalmitis: a study of 36 cases with special reference to antibiotic resistance and treatment options. / Clin Microbiol Infec 2006, 12:519-26. CrossRef
10. Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Corey RP, Miller D: Endophthalmitis caused by Streptococcus pneumoniae . / Am J Ophthalmol 2004, 138:231-36. CrossRef
11. Johnson S, Rubin L, Romero-Steiner S, Dykes J, Pais L, Rizvi A, Ades E, Carlone G: Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae . / J Infect Dis 1999, 180:133-40. CrossRef
12. Kadioglu A, Taylor S, Iannelli F, Pozzi G, Mitchell TJ, Andrew PW: Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. / Infect Immun 2002, 70:2886-890. CrossRef
13. Lindberg J, Fangel S: Recurrent endocarditis caused by Streptococcus pneumoniae . / Scand J Infect Dis 1999, 31:409-10. CrossRef
14. Llull D, Lopez R, Garcia E: Genetic bases and medical relevance of capsular polysaccharide biosynthesis in pathogenic streptococci. / Curr Mol Med 2001, 1:475-91. CrossRef
15. Varon E: Severe pneumococcal infections: virulence aspects. / Arch Pediatr 2001,8(Suppl 4):752s-756s. CrossRef
16. Magee AD, Yother J: Requirement for capsule in colonization by Streptococcus pneumoniae . / Infect Immun 2001, 69:3755-761. CrossRef
17. Nuorti JP, Whitney CG: Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). / MMWR Recomm Rep 2010, 59:1-8.
18. Robbins JB, Austrian R, Lee C-J, Rastogi SC, Schiffman G, Henrichsen J, Makela PH, Broome CV, Facklam RR, Tiesjema RH, Parke JC: Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. / J Infect Dis 1983, 148:1136-159. CrossRef
19. Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA, on behalf of the 004 Study Group: Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. / Pediatrics 2010, 126:e493-e505. CrossRef
20. Jeurissen A, Wuyts M, Kasran A, Ramdien-Murli S, Boon L, Ceuppens JL, Bossuyt X: Essential role for CD40 ligand interactions in T lymphocyte-mediated modulation of the murine immune response to pneumococcal capsular polysaccharides. / J Immunol 2002, 168:2773-781.
21. Sanders M, Norcross EW, Robertson ZM, Moore QC III, Fratkin J, Marquart ME: The Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitis. / Invest Ophthalmol Vis Sci 2011, 52:865-72. CrossRef
22. Tweten RK: Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. / Infect Immun 2005, 73:6199-209. CrossRef
23. Kelly S, Jedrzejas M: Structure and molecular mechanism of a functional form of pneumolysin: a cholesterol-dependent cytolysin from Streptococcus pneumoniae . / J Struct Biol 2000, 132:72-1. CrossRef
24. Baba H, Kawamura I, Kohda C, Nomura T, Ito Y, Kimoto T, Watanabe I, Ichiyama S, Mitsuyama M: Essential role of domain 4 of pneumolysin from Streptococcus pneumoniae in cytolytic activity as determined by truncated proteins. / Biochem Biophys Res Commun 2001, 281:37-4. CrossRef
25. Bonev BB, Gilbert RJC, Andrew PW, Byron O, Watts A: Structural analysis of the protein/lipid complexes associated with pore formation by the bacterial toxin pneumolysin. / J Biol Chem 2001, 276:5714-719. CrossRef
26. Ng EW, Samiy N, Rubins JB, Cousins FV, Ruoff KL, Baker AS, D'Amico DJ: Implication of pneumolysin as a virulence factor in Streptococcus pneumoniae endophthalmitis. / Retina 1997, 17:521-29.
27. Ng EW, Costa JR, Samiy N, Ruoff KL, Connolly E, Cousins FV, D'Amico DJ: Contribution of pneumolysin and autolysin to the pathogenesis of experimental pneumococcal endophthalmitis. / Retina 2002, 22:622-32. CrossRef
28. Sanders M, Norcross E, Moore Q, Fratkin J, Thompson H, Marquart M: Immunization with pneumolysin protects against both retinal and global damage caused by Streptococcus pneumoniae endophthalmitis. / J Ocul Pharmacol Ther 2010, 26:571-77. CrossRef
29. Norcross E, Sanders ME, Moore Q, Taylor S, Tullos N, Caston R, Dixon S, Nahm M, Burton R, Thompson H, McDaniel L, Marquart M: Active immunization with pneumolysin versus 23-valent polysaccharide vaccine for Streptococcus pneumoniae keratitis. / Invest Ophthalmol Vis Sci 2011, 52:9232-243. CrossRef
30. Thornton J, McDaniel LS: THP-1 monocytes up-regulate intercellular adhesion molecule 1 in response to pneumolysin from Streptococcus pneumoniae . / Infect Immun 2005, 73:6493-498. CrossRef
31. Zhang Q, Choo S, Finn A: Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. / Infect Immun 2002, 70:5363-369. CrossRef
32. Rodriguez-Barradas MC, Musher DM, Lahart C, Lacke C, Groover J, Watson D, Baughn R, Cate T, Crofoot G: Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. / J Infect Dis 1992, 165:553-56. CrossRef
33. Callegan MC, Jett BD, Hancock LE, Gilmore MS: Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model. / Infect Immun 1999, 67:3357-366.
34. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J: Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. / J Antimicrob Chemother 2006, 58:117-24. CrossRef
35. Hobden JA, Hill JM, Engel LS, O'Callaghan RJ: Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen. / Antimicrob Agents Chemother 1993, 37:1856-859. CrossRef
36. Crowder M, Hand DJ: Monographs on statistics and applied probability 41. In / Analysis of repeated measures. 1st edition. Boca Raton: Chapman & Hall/CRC; 1990:268.
37. Edwards DBJ: The Efficiency of Simulation-Based Multiple Comparisons. / Biometrics 1987, 43:913-28. CrossRef
38. DJ S: / Handbook of Parametric and Nonparametric Statistical Procedures. Boca Raton: Chapman & Hall/CRC; 2000.
39. Mondino B, Sidikaro Y, Sumner H: Anaphylatoxin levels in human vitreous humor. / Invest Ophthalmol Vis Sci 1988, 29:1195-198.
40. Green K, Paterson C, Cheeks L, Slagle T, Jay W, Aziz M: Ocular blood flow and vascular permeability in endotoxin-induced inflammation. / Ophthalmic Res 1990, 22:287-94. CrossRef
41. Bora N, Gobleman C, Atkinson J, Pepose J, Kaplan H: Differential expression of the complement regulatory proteins in the human eye. / Invest Ophthalmol Vis Sci 1993, 34:3579-584.
42. Huo Z, Miles J, Riches P, Harris T: Limitations of Pneumovax(R) as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay. / Ann Clin Biochem 2002, 39:398-03. CrossRef
43. Steinitz M, Tamir S, Goldfarb A: Human anti-pneumococci antibody produced by an Epstein Barr virus (EBV)- immortalized cell line. / J Immunol 1984, 132:877-82.
44. Benz M, Scott I, Flynn H, Unonius N, Miller D: Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. / Am J Ophthalmol 2004, 137:38-2. CrossRef
45. Aaberg T, Flynn H, Schiffman J, Newton J: Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. / Ophthalmology 1998, 105:1004-010. CrossRef
46. Ang G, Barras C: Prophylaxis against infection in cataract surgery: a survey of routine practice. / Eur J Ophthalmol 2006, 16:394-00.
47. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2415/13/8/prepub - 作者单位：Melissa E Sanders (1)
Sidney Taylor (1)
Nathan Tullos (1)
Erin W Norcross (1)
Quincy C Moore (1)
Hilary Thompson (2)
Lauren B King (1)
Mary E Marquart (1)
1. Department of Microbiology, University of Mississippi Medical Center, Jackson, MS, 39216, USA
2. Department of Biometry, Louisiana State University Health Sciences Center School of Public Health, New Orleans, LA, 70112, USA
文摘
Background Capsule and pneumolysin (PLY) are two major virulence factors of Streptococcus pneumoniae. S. pneumoniae is one of the leading causes of bacterial endophthalmitis. The aim of this study is to determine whether passive immunization with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax? 23; PPSV23) or PLY protects against pneumococcal endophthalmitis. Methods New Zealand white rabbits were passively immunized with antiserum to PLY, PPSV23, a mixture of PPSV23/PLY, or PBS (mock). Vitreous was infected with a clinical strain of S. pneumoniae. In a separate group of experiments, vancomycin was injected 4?hours post-infection (PI) for each passively immunized group. Severity of infection, bacterial recovery, myeloperoxidase (MPO) activity and percent loss of retinal function were determined. Results Passive immunization with each antiserum significantly lowered clinical severity compared to mock immunization (PPSV23--.19, PPSV23/PLY--0.45, PLY--.71, Mock--6.83; P--.0467). A significantly higher bacterial load was recovered from the vitreous of PLY passively immunized rabbits 24?hours PI (7.87 log10 CFU) compared to controls (7.10 log10 CFU; P--.0134). Retinas from immunized rabbits were more intact. Vitreous of PLY (2.88 MPO untis/mL) and PPSV23/PLY (2.17) passively immunized rabbits had less MPO activity compared to controls (5.64; P--.0480), and both passive immunizations (PLY--1.34% loss of retinal function, PPSV23/PLY--7.44%) helped to significantly preserve retinal function compared to controls (64.58%; P--.0323). When vancomycin was administered 4?hours PI, all eyes were sterile at 24?hours PI. A significantly lower clinical severity was observed for rabbits administered the combination immunization (5.29) or PPSV23 (5.29) with vancomycin treatment compared to controls (17.68; P--.0469). Conclusions Passive immunization with antisera to these antigens is effective in reducing clinical severity of pneumococcal endophthalmitis in rabbits. Addition of vancomycin to immunization is effective at eliminating the bacteria.